ALNY Key Statistics, Chart & Performance
The current stock price of ALNY is 338.06 USD. In the past month the price decreased by -14.99%. In the past year, price increased by 24.6%.
ALNY Technical Analysis
ALNY Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ALNY. ALNY has an average financial health and profitability rating.
ALNY Financial Highlights
Over the last trailing twelve months ALNY reported a non-GAAP Earnings per Share(EPS) of 0.51. The EPS increased by 119.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.36% | ||
| ROA | 0.9% | ||
| ROE | 18.63% | ||
| Debt/Equity | 10.22 |
ALNY Forecast & Estimates
36 analysts have analysed ALNY and the average price target is 496.56 USD. This implies a price increase of 46.88% is expected in the next year compared to the current price of 338.06.
For the next year, analysts expect an EPS growth of 209.79% and a revenue growth 68% for ALNY
ALNY Ownership
ALNY Latest News, Press Relases and Analysis
About ALNY
Company Profile
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,230 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
Company Info
ALNYLAM PHARMACEUTICALS INC
675 W Kendall St
Cambridge MASSACHUSETTS 02142 US
CEO: John M. Maraganore
Employees: 2230
Phone: 16175518200
ALNYLAM PHARMACEUTICALS INC / ALNY FAQ
Can you describe the business of ALNYLAM PHARMACEUTICALS INC?
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,230 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
What is the current price of ALNY stock?
The current stock price of ALNY is 338.06 USD. The price decreased by -2.52% in the last trading session.
Does ALNYLAM PHARMACEUTICALS INC pay dividends?
ALNY does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALNY stock?
ALNY has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Would investing in ALNYLAM PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALNY.
How many employees does ALNYLAM PHARMACEUTICALS INC have?
ALNYLAM PHARMACEUTICALS INC (ALNY) currently has 2230 employees.
Can you provide the market cap for ALNYLAM PHARMACEUTICALS INC?
ALNYLAM PHARMACEUTICALS INC (ALNY) has a market capitalization of 44.66B USD. This makes ALNY a Large Cap stock.